Gene · 1488
CTBP2: C-terminal binding protein 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CTBP2: C-terminal binding protein 2. Genes, record 1488. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1488
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P56545 | C-terminal-binding protein 2 | 445 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents62
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 6368 | P56545 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6123 | P56545 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6123 | P56545 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6368 | P56545 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5683 | P56545 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5684 | P56545 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5685 | P56545 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 5687 | P56545 | Espacenet |
| US 11884978 B2 | 2024-01-30 | 481 | P56545 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 20505 | P56545 | Espacenet |
1 to 10 of 62
See all 62 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,169
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CTBP2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016059 | Massey Cancer Center - Cancer Center Support Grant | 7 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 3 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 3 | 2025 |
| P30EY001730 | Vision Research Core | 3 | 2025 |
| P50CA097186 | The Pacific Northwest Prostate Cancer SPORE | 3 | 2025 |
| R01DC000188 | Cochlear synaptopathy in noise-induced and age-related hearing loss: mechanisms and treatments | 3 | 2025 |
| R01EY012857 | Regulation of Retinal Gap Junctions | 3 | 2025 |
1 to 10 of 1,169Source NIH's project files
See all 1,169 nih grantsPapers1,330
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Delineating the CTBP1-Related Phenotypic Spectrum: A Review of HADDTS and Atypical Variants. | Int J Mol Sci | 2026 | 42589715 | PubTator, text mining | PubMed |
| Terminal 4q duplication and extended 10q deletion in a preterm infant with linear growth restriction: transcriptomic evidence of disrupted developmental and metabolic pathways. | Front Pediatr | 2026 | 42395604 | PubTator, text mining | PubMed |
| Consistent Metabolomic and Genetic Evidence Supports Acisoga as a Key Contributor to Colorectal Neoplasia Progression. | Cancer Epidemiol Biomarkers Prev | 2026 | 42201318 | PubTator, text mining | PubMed |
| First large-scale screening of Notch biallelic variants implicates novel candidate genes in congenital hypothyroidism. | J Clin Endocrinol Metab | 2026 | 42192612 | PubTator, text mining | PubMed |
| Retraction: CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelialmesenchymal transition in hepatocellular carcinoma. | Oncotarget | 2026 | 42030155 | PubTator, text mining | PubMed |
| Retinal ribbon synapses and the potential functional role of TIAM1: A structural and molecular perspective. | Mol Vis | 2026 | 41982461 | PubTator, text mining | PubMed |
| Functional roles and mechanisms of circRNA-protein interactions in cancer progression and tumor immune regulation. | Front Immunol | 2026 | 41756268 | PubTator, text mining | PubMed |
| Loss of Cathepsin K Impairs Collagen Biogenesis and Enhances Actin Polymerization in Trabecular Meshwork. | Invest Ophthalmol Vis Sci | 2026 | 41615370 | PubTator, text mining | PubMed |
| Synaptic control of retinal ganglion cell survival and axon regeneration. | Mol Neurodegener | 2026 | 41606681 | PubTator, text mining | PubMed |
| Molecular mechanisms and clinical insights of benzo[a]pyrene-related lung adenocarcinoma: New discoveries in multi-scale approaches. | Ecotoxicol Environ Saf | 2026 | 41601038 | PubTator, text mining | PubMed |
1 to 10 of 1,330
See all 1,330 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1488
GET https://conductscience.org/api/genes/v1/1488/patents?page=2